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Abstract
Introduction: Current guidelines recommend completion axillary lymph node dissection (cALND) in case of a sentinel lymph node 
(SLN) metastasis larger than 0.2 mm. However, in 50%–65% of these patients, the non-SLNs contain no further metastases and cALND 
provides no benefit. Several nomograms and scoring systems have been suggested to predict the risk of metastases in non-SLNs. We 
have evaluated the Tenon score.
Patients and Methods: In a retrospective review of the Swedish Sentinel Node Multicentre Cohort Study, risk factors for additional 
metastases were analysed in 869 SLN-positive patients who underwent cALND, using uni- and multivariate logistic regression models. 
A receiver operating characteristic (ROC) curve was drawn on the basis of the sensitivity and specificity of the Tenon score, and the area 
under the curve (AUC) was calculated.
Results: Non-SLN metastases were identified in 270/869 (31.1%) patients. Tumour size and grade, SLN status and ratio between num-
ber of positive SLNs and total number of SLNs were significantly associated with non-SLN status in multivariate analyses. The area 
under the curve for the Tenon score was 0.65 (95% CI 0.61–0.69). In 102 patients with a primary tumour ,2 cm, Elston grade 1–2 and 
SLN metastases #2 mm, the risk of non SLN metastasis was less than 10%.
Conclusion: The Tenon score performed inadequately in our material and we could, based on tumour and SLN characteristics, only 
define a very small group of patients in which negative non-sentinel nodes could be predicted.
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Introduction
Sentinel lymph node biopsy (SLNB) has widely replaced 
conventional axillary lymph node dissection (ALND) as 
routine axillary staging in breast cancer surgery. The 
SLNB method is accurate and safe1–4 and conveys sub-
stantially less postoperative morbidity than ALND.5,6
Current guidelines recommend completion axillary 
lymph node dissection (cALND) in case of a sentinel 
lymph  node  (SLN)  metastasis  larger  than  0.2 mm.7 
However, in 50%–65% of patients, the non-SLNs con-
tain no further metastases8 and cALND provides no 
benefit. In addition, several studies have demonstrated 
the incidence of regional recurrence to be much lower 
than expected when axillary surgery was omitted,9–12 
and the need for cALND in all SLN-positive patients 
has been questioned. It remains, though, that even in 
the case of only SLN isolated tumour cells, the inci-
dence of non-SLN metastases has been reported to be 
as high as 20%.13 The benefit of ALND on survival is 
debated.  In  a  meta-analysis  from  the  pre-SLN  era, 
ALND improved survival,14 but in some latter, ran-
domized, pre-SLN studies, the survival was similar in 
the  ALND  and  the  no  ALND  groups.15,16  Giuliano 
et al17 reported that SLNB alone does not result in infe-
rior survival in SLN-positive patients, and in a recent 
review it was concluded that there is a potential role for 
avoiding ALND in selected SLN-positive patients.18
Several authors have suggested nomograms and 
scoring systems to predict the risk of non-SLN metas-
tases, with the aim of aiding in the decision of further 
surgery.19–25 Validation studies have   demonstrated a 
reasonably  accurate  predictive  ability,26–33  although 
far from perfect. In a comparison by   Coutant et al, the 
Memorial Sloan-Kettering Cancer Center nomogram 
and  Tenon  score  outperformed  other  predictive 
  models.27 An advantage of the Tenon score is that a 
fair estimation of all predictive variables can be made 
perioperatively,  allowing  the  surgeon  to  decide 
whether  cALND  should  be  performed  directly 
  following frozen section of the SLN.
In the present study we evaluated the Tenon score 
in a large Swedish multicentre SLN cohort.
patients and Methods
The swedish sentinel node multicentre 
cohort study
Between September 2000 and January 2004, 3501 
women (with 3535 breast tumours) from 25 Swedish 
hospitals were included in the Swedish Sentinel Node 
Multicentre Cohort Study. Patients and surgical meth-
ods  have  been  described  in  detail  elsewhere.34  In 
short, patients with a unifocal, invasive breast cancer 
less than 3 cm in diameter were eligible for   enrolment. 
Exclusion  criteria  were  palpable  regional  lymph 
nodes,  neoadjuvant  chemo-  or  radiotherapy,  preg-
nancy, known allergic reactions to blue dye or iso-
tope, previous surgery in the ipsilateral breast, and 
preoperatively diagnosed tumour multifocality. After 
enrolment, data sheets were sent to a research unit, 
where they were computerised. Data sheets included 
information on primary tumour characteristics, num-
ber of sentinel and non-sentinel lymph nodes with 
and without metastasis, and size of metastasis. The 
research protocol postulated annual follow-ups with 
mammography and clinical examination. Incidence 
of recurrences and survival were prospectively fol-
lowed up by a research assistant via reports from the 
participating centres and on-site visits.
The study was approved by the ethics committee 
of Karolinska Institutet, Stockholm, and each region’s 
local  ethics  committee.  All  patients  gave  written 
informed consent.
Surgical procedure
After the preoperative sub- or intradermal injection of 
40–60  mBq  Technetium-99  nanocolloid  (Solco 
  Nanocoll®) and 1 ml blue dye (Patent Blue V®), SLNB 
was performed. If no sentinel node could be identi-
fied,  ALND  of  levels  I  and  II  was  performed. 
A cALND was performed in the event of a positive 
SLNB diagnosed peri- or postoperatively, or if the 
primary tumour in the breast was found to be multifo-
cal on pathological examination.
Pathological assessment
Frozen sections were obtained from each SLN and 
examined during surgery. If a sentinel lymph node 
was smaller than 4 mm, two sections were analysed 
separately. Nodes larger than 4 mm were bisected, 
and  two  sections  from  each  half  analysed.  For 
  paraffin-embedded histopathology, at least three sec-
tions were prepared from the sentinel node or each 
part of a bisected node. Sections were stained with 
haematoxylin and eosin (HE). If no cancer cells were 
detected, immunohistochemistry (IHC) with cytok-
eratin antibodies was also performed.non-SLn status in SLn-positive breast cancer patients
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Non-sentinel  lymph  nodes  were  examined  by 
  routine staining (HE) according to the protocol of 
each pathology department.
At the time of inclusion into the cohort, pathologists 
rarely  differentiated  micrometastases  from  isolated 
tumour cells. To update the classification of metastases 
for the present study according to the revised American 
Joint Committee on Cancer Staging System for Breast 
Cancer,35 all pathology reports describing SLN micro-
metastases  after  routine  pathological  work-up  were 
scrutinised by a breast pathologist and three surgeons. 
When differentiation was not possible from the origi-
nal report, original slides were re-examined and re-
classified by the pathologist. Four groups of patients 
were identified based on the finding in the SLN: node-
negative  (pN0),  isolated  tumour  cells  (,0.2  mm, 
pN0(i+)), micrometastases (0.2–2 mm, pN1mi), and 
macrometastases (.2 mm, pN1).
The present analysis
For the present study, a positive SLN was defined as 
any SLN containing tumour cells, including isolated 
tumour cells. Patients who had at least one positive 
SLN and underwent cALND were included from the 
prospective  database.  Patients  with  positive  non-
SLNs were compared with those who had negative 
non-SLNs regarding age, size, histological type and 
grade of the primary tumour, oestrogen and proges-
terone  receptor  status,  the  number  of  positive  and 
negative SLNs and SLN status.
The Tenon score was calculated for all patients by 
adding the point values for the presence of macrome-
tastases in the SLN (yes = 2, no = 0), the histological 
tumour size in mm (.20 = 3, 11–20 = 1.5, ,11 = 0) 
and the ratio between positive and total SLNs (1 = 2, 
0.5–1 = 1, ,0.5 = 0).19 Applying the recommended 
threshold value of 3.5 or less, the predicted non-SLN 
status was compared with the actual status.
The incidence of axillary recurrence was compared 
with a smaller group of patients from the same SLN 
cohort who were diagnosed with SLN metastases but 
did not undergo cALND (n = 86).
Statistical analysis
Continuous variables (age, tumour size and number 
of SLNs), dichotomous variables (oestrogen and pro-
gesterone receptor status) and categorical variables 
(histological type and grade of the tumour, SLN   status 
and ratio score between number of positive and total 
number of SLNs as defined in the Tenon score) were 
analysed in a univariate logistic regression model. All 
variables that demonstrated a statistically significant 
difference in univariate tests were then analysed in a 
multivariable regression model. A receiver operating 
characteristic (ROC) curve was drawn on the basis of 
the sensitivity and specificity of the Tenon score, and 
the area under the curve (AUC) was calculated.
SPSS 14.0® software was used for all analyses 
and statistical significance was set at the 0.05 level 
for all tests.
Results
Patient and tumour characteristics are given in Table 1. 
We identified 869 patients with SLN metastases where 
cALND was performed (282 cALNDs in a second 
session). Most of these patients (n = 691) had SLN 
macrometastases, but 20% (178/869) had metastases 
of #2 mm (11% micrometastases (98/869) and 9% 
isolated tumour cells (80/869), Table 2).
Additional axillary metastases
Non-SLN  metastases  were  identified  in  270/869 
(31.3%) patients, and 251/691 (36.3%) of the pN1, 
11/98 (11.2%) of the pN1mi, and 8/80 (10.0%) of the 
pN0(i+) patients. Of these, non-SLN macrometasta-
ses were revealed in 8/11 (72.7%) of the pN1 mi and 
3/8 (37.5%) of the pN0(i+) patients. The proportions 
of positive non SLNs according to total number of 
SLNs  and  number  of  positive  SLNs  are  given  in 
Table 3.
We identified two groups of patients where the risk 
of non-SLN metastases was less than 10%. In pN1mi 
or pN0(i+) patients with a tumour smaller than 2 cm 
and Elston grade 1 or 2 (n = 102), it was 6.7%, and in 
pN1mi or pN0(i+) patients with more than two SLNs 
removed (n = 23), it was 6.0%.
Correlation between clinicopathologic 
characteristics and positive non-SLns
Tumour size and grade, SLN status and ratio between 
the  number  of  positive  SLNs  and  total  number  of 
SLNs were significantly associated with non-SLN sta-
tus, both in uni- and multivariate analyses.   Histotype 
was significant only in the univariate analysis. P-  values 
for the association between different characteristics 
and  non-SLN  positivity  are  given  in  Table  1. Andersson et al
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Figure 1. The receiver operation curve (ROC) for 869 sentinel lymph 
node-positive patients calculated for the Tenon score; blue line, area 
under the curve (AUC) 0.65. The green, diagonal line represents AUC 
0.5 (flipping a coin).
Table 1. Patient and tumour characteristics in 869 SLn-
positive patients who underwent completion axillary lymph 
node dissection.
non-sentinel lymph node status
characteristics 
n
positive 
non-sn 
270
negative 
non-sn 
599
Pd
Age (years)a 57 (28–82) 57 (28–90) 0.481
Tumour size (mm)b 19 (10) 17 (8) ,0.001
histotypec 0.035
  Ductal  173 (64.1) 408 (68.1)
  Lobular 49 (18.1) 75 (12.5)
  Mixed 2 (0.7) 10 (1.7)
  Other 11 (4.1) 30 (5.0)
  Missing 35 (13.0) 76 (12.6)
Tumour grade  
(elston grade)c
,0.001
 1 38 (14.1) 152 (25.3)
 2 138 (51.1) 304 (50.8)
 3 88 (32.6) 128 (21.4)
  Missing 6 (2.2) 15 (2.5)
Oestrogen  
receptorc
0.502
  Positive 231 (85.6) 520 (86.8)
  negative 37 (13.7) 72 (12.0)
  Missing 2 (0.7) 7 (1.2)
Progesterone  
receptorc
0.696
  Positive 185 (68.5) 425 (71.0)
  negative 80 (29.6) 160 (26.7)
  Missing 5 (1.9) 14 (2.3)
number of SLnsa 2 (1–9) 2 (1–8) 0.872
Mean number of pos. 
SLns/total SLns
0.81 0.71 ,0.001
notes:  aMedian  (range);  bMean  (standard  deviation);  cnumber  (%); 
dUnivariate analysis.
Abbreviation: SLn, sentinel lymph node.
Table 2. Sentinel lymph node (SLn) status in 869 SLn-
positive patients who underwent completion axillary lymph 
node dissection.
non-sentinel lymph node status
sLn statusa positive non-sn negative non-sn
n = 270 n = 599
pn0(i+)b 8 (3.0) 72 (12.0) 78
pn1 mic 11 (4.0) 87 (14.5) 98
pn1d 251 (93.0) 440 (73.5) 691
notes: anumber (%); b,0.2 mm; c0.2–2 mm; d.2 mm.
The risk of positive non-SLNs was 4.66 times higher 
for patients with SLN macrometastases than for those 
with  SLN  micrometastases  (95%  CI  2.18–9.95, 
P , 0.001) and 2.79 times higher for a high positive/
total SLN ratio as defined in the Tenon score (95% CI 
1.69–4.60, P , 0.001). The hazard ratio for increasing 
tumour diameter (per millimetre) was 1.02 (95% CI 
1.00–1.04,  P  =  0.035)  and  for  high  tumour  grade 
(Elston  grade  3  vs.  1)  2.41  (95%  CI  1.51–3.86, 
P , 0.001).
Tenon score
The mean Tenon score was 5.29 in patients with non-
SLN metastases and 4.49 in those without (P , 0.001). 
Applying a threshold value of 3.5, the specificity was 
34.6%  and  the  sensitivity  was  85.9%.  The  false 
negative rate was thus 14.1% (38/245 patients with a 
Tenon score 3.5 or less had non-SLN metastases).
The  area  under  the  curve  was  0.65  (95% 
CI 0.61–0.69) for all patients (Fig. 1), 0.63 (95% CI 
0.59–0.67)  for  patients  with  SLN  micro-  and 
  macrometastases,  0.57  (95%  CI  0.44–0.70)  for 
patients with SLN metastases of #2 mm, and 0.54 
(95% CI 0.37–0.72) for pN1 mi patients only.
Axillary recurrences
In the study group, there were 10/869 (1.2%) isolated 
axillary recurrences (8/691 (1.2%) in pN1 and 2/98 
(2.0%) in pN1mi patients) after 56.3 months median 
follow-up. Almost all patients (860/869, 99.0%) had non-SLn status in SLn-positive breast cancer patients
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Table 3. Cross tabulation of number of positive sentinel lymph nodes (SLns) by total number of SLns removed. each cell 
represents the proportion of patients with positive non SLn. 
number of positive sLns
number of  
sLns
1 2 3 4 5 6 7 n
1 86/281 
(31%)
281
2 53/196 
(27%)
56/130 
(43%)
326
3 14/92 
(15%)
15/43 
(35%)
17/30 
(57%)
165
4 4/33 
(12%)
4/15 
(27%)
2/6 
(33%)
6/8 
(75%)
62
5 2/8 
(25%)
1/5 
(20%)
2/3 
(67%)
3/3 
(100%)
1/2 
(50%)
21
6 0/2 
(0)
1/3 
(33%)
0/1 
(0)
_ _ 1/2 
(50%)
8
7 _ 0/1 
(0)
0/2 
(0)
_ _ _ _ 3
8 0/1 
(0)
1/1 
(100%)
_ _ _ _ _ 2
9 _ _ _ _ _ _ 1/1 
(100%)
1
note: n, number of patients.
adjuvant treatment (81.5% radiation, 83.2% hormonal 
treatment and 49.4% chemotherapy).
In a separate group of 86 patients with SLN metas-
tases in whom ALND was omitted (mean Tenon score 
3.11), 1/86 (1.2%) patient had an isolated axillary 
recurrence after 51.8 months median follow-up. In 
this  group,  82/86  (95.3%)  had  adjuvant  treatment 
(68.6%  radiation,  86.0%  hormonal  treatment  and 
5.8% chemotherapy).
Discussion
Several authors have, by creating nomograms and 
scoring  systems,  attempted  to  define  a  subset  of 
SLN-positive  patients  in  whom  cALND  could 
safely be omitted. The Tenon score outperformed 
other scoring systems in a study by Coutant et al27 
and includes characteristics that can be estimated at 
the time of the SLN biopsy. In the present study, we 
evaluated the Tenon score in a Swedish multicentre 
cohort. The AUC  was  only  0.65  and  the  perfor-
mance  of  the  score  was  thus  inadequate  in  our 
patient cohort.
A validation study demonstrating good accuracy 
of the Tenon score was also presented by Coutant 
et al,36 with both studies from this group evaluating 
French populations. A French data set was also used 
to develop the Tenon score. In contrast, validation 
studies in other populations and also a recent French 
validation study demonstrate less prediction accuracy 
(AUC 0.58–0.70),29,37–39 which the results from our 
study are in accordance with. This could represent 
differences  in  populations,  surgical  technique  or 
pathologic examination.
Unfortunately,  we  were  not  able  to  validate  the 
Memorial  Sloan-Kettering  Cancer  Center  (MSKCC) 
nomogram24 in our population as we had incomplete 
information  about  the  occurrence  of  lymphovascular 
invasion. The MSKCC nomogram has, however, been 
validated in several other studies, and the AUC varied 
between 0.58 and 0.86.27,39 In three studies the AUC was 
less than 0.70 (the limit used for considering an accept-
able predictive ability), possibly reflecting population 
differences in a similar way as for the Tenon score.
Several studies have tried, but have been unable, 
to define a subgroup in which cALND can safely be 
omitted.8,13,40–43 In a meta-analysis by Degnim et al,8 
no subgroup had less than a 10% risk of non-SLN 
metastases.
We could identify two groups of patients in whom 
the  risk  of  non-SLN  metastases  was  less  than  10%. 
However, these were very small subgroups (n = 102 and 
23, respectively) that were not pre-planned in the study Andersson et al
36  Breast Cancer: Basic and Clinical Research 2012:6
and their clinical significance is therefore questionable. 
The results of our study, and most of the previously pub-
lished, similar studies, indicate that the evaluation of pri-
mary tumour and SLN characteristics is not sufficient to 
decide whether to proceed with further axillary surgery.
Interestingly, only one of 86 SLN-positive patients 
in whom cALND was omitted had an isolated axil-
lary recurrence. In accordance, a low incidence of 
axillary recurrence was previously demonstrated in 
other studies.10,12,44 In a review by Rutgers, the 2- to 
3-year  risk  of  axillary  recurrence  in  SLN-positive 
patients was 0 to 1.4% if the axilla was left   untreated.45 
In part, this could be explained by better prognostic 
factors in the patients that did not have cALND, but 
many studies have reported the axillary recurrence 
rate to also be lower than expected in SLN-  negative 
patients. Since the false negative rate is known to 
be about 5%–10%4,46–48 this indicates that not all posi-
tive lymph nodes left behind will develop into clini-
cally significant metastases.
Recently, in a report on 97 314 patients who had 
breast  cancer  surgery  between  1998  and  2005, 
  Bilimoria  et  al49  found  no  significant  difference  in 
  axillary  recurrence  or  survival  for  SLN-positive 
patients who underwent SLNB alone compared with 
those who had cALND. It is, however, a retrospective 
study  and  the  completeness  of  follow-up  was  not 
reported. Furthermore, between 1998 and 2000 the 
number of excised lymph nodes was almost as high in 
the SLNB as in the ALND group.
Additionally, the American College of Surgeons 
Oncology Group (ACO-SOG) Z0011 trial found no 
higher incidence of axillary recurrence50 and compa-
rable survival17 in SLN-positive patients randomised 
to  omission  of  cALND  compared  with  those  who 
completed  an ALND  after  a  median  follow-up  of 
6.3 years. However, only 891 of the planned 1900 
patients were accrued and the study was closed early. 
Considering the low accruement rate (despite many 
participating centres, several of these probably with 
large patient volumes), one cannot rule out the possi-
bility  of  a  significant  selection  bias,  and  included 
patients were at low risk for recurrence. Furthermore, 
all patients received whole-breast irradiation, includ-
ing the lower part of the axilla.
We therefore believe that it is too early to abandon 
ALND for all SLN-positive patients.
conclusion
The Tenon score performed inadequately in our mate-
rial and we could only define a very small group of 
patients  in  which  negative  non-SLNs  could  be 
predicted.
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